Most notably, we completed U.S. and Japanese filings for crizotinib in ALK-positive non-small cell lung cancer and U.S. and EU filings for axitinib in advanced renal cell carcinoma.
In one patient whose cancer spread on crizotinib, doctors were able to treat the brain tumor with radiation while the rest of the tumors remained under control with the drug.
There is promise there, particularly in the lung cancer drug crizotinib, which is being submitted to the Food and Drug Administration, and to Prevnar, the vaccine against pneumococcal disease, which is being tested in adults.